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Abstract 
The role of norepinephrine (NE) has recently received increasing attention in the context 
of alcohol misuse and how this may transform into alcohol dependence. In order to assess the 
pharmacological potential of the NE system in the prevention of alcohol abuse, we must have a 
more precise understanding of the neurobiological pathways involved. Previous research 
suggests that the locus coeruleus (LC) – lateral hypothalamus (LH) pathway may be particularly 
important in mediating the excessive use of alcohol, known as binge drinking. Using the 
“drinking in the dark” (DID) procedure, we evaluated the effects of two different NE-increasing 
drugs on the ethanol and sucrose intake of C57BL/6J mice. Atipamezole, an alpha-2 
adrenocepter (AR) antagonist, was infused directly into the LH, decreasing ethanol and sucrose 
consumption in females exclusively. In a second study, the noradrenergic reuptatke inhibitor, 
reboxetine, was administered systemically to determine if increasing NE activity throughout the 
body alters binge-like ethanol consumption. Reboxetine significantly reduced ethanol and 
sucrose intake across all subjects, indicating that NE signaling may be a useful target for 
modulating excessive ethanol and/or general consummatory behavior. While the results suggest 
that increasing NE signaling may be an effective method to reduce alcohol intake, further 
investigation is needed regarding the relative influence of specific brain pathways and which 
mechanisms will maximize the selectivity for preventing alcohol dependence.   
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Effects of alpha-2 adrenergic receptors on subsequent binge-like alcohol intake 
Throughout the world, alcohol misuse presents burdens in a multitude of ways. Perhaps 
the most pressing of these issues is the fact that alcohol consumption has been linked to a 
number of acute and chronic health concerns, many of which are fatal. In fact, it is among the top 
preventable causes of death, accounting for approximately 88,000 deaths in the United States 
every year (CDC, 2013). Alcoholic liver disease and motor vehicle crashes are responsible for 
the largest portion of these alcohol-related fatalities (CDC), but this should not undermine the 
multitude of other adverse health outcomes associated with alcohol intake. For instance, alcohol 
use predicts immediate health-risk behaviors such as smoking, using illicit substances and 
engaging in unprotected sexual intercourse (Assanangkornch, Mukthong & Intanont, 2009), as 
well as more chronic issues including several life-threatening diseases (Jennison, 2004). 
According to the World Health Organization (WHO, 2014), alcohol use was linked to more than 
200 diseases and injury-related health conditions in 2014 – most significantly, alcohol use 
disorder (AUD), which consists of alcohol abuse and alcohol dependence (APA, 2013).  
Despite alcohol use’s contribution to such diseases, an even greater predictor of these 
negative outcomes has been revealed more recently: binge drinking. The National Institute on 
Alcohol Abuse and Alcoholism (NIAAA) defines binge drinking as “a pattern of drinking that 
brings blood alcohol concentration (BAC) levels to 0.08% (0.08 g/dL) (2004).” This typically 
occurs after 5 or more alcoholic drinks for males or 4 or more alcoholic drinks for females on the 
same occasion (SAMHSA, 2016). Adding such “binge” criteria significantly increases drinkers’ 
likelihood of experiencing negative effects of drinking, as this particular pattern of drinking has 
been more strongly correlated with many of the effects of alcohol intake previously discussed. 
For example, compared to non-binge drinkers, binge drinkers are more likely to take part in risky 
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behaviors including driving under the influence, sexually assaulting or raping another individual, 
and attempting to commit suicide (Assanangkornch, Mukthong, & Intanont, 2009), More 
generally, binge drinking is associated with a poorer health-related quality of life and mental 
distress (i.e. stress, depression and emotional problems) (Okora et al., 2004). Perhaps the most 
enduring of such consequences, however, is the fact that individuals who engage in binge 
drinking are much more likely to become alcohol-dependent later in life (NIAAA, 2006).  
There is evidence that individuals tend to reduce, if not cease, alcohol consumption when 
experiencing a decline in health (Liang & Chikritzhs, 2011), suggesting that people are generally 
aware of the harmful effects of alcohol intake. Nevertheless, over 25 percent of individuals 18 
years or older admit to having engaged in binge drinking in the past month (SAMHSA, 2015), 
and a recent study published by JAMA Psychiatry indicates that the problem is worsening 
(2017). As attitudes towards drinking are becoming increasingly permissive, rates of alcohol use, 
binge drinking, and AUD have risen dramatically since 2002 (Grant et al., 2017). Moreover, the 
average intensity of binge drinking nearly doubles the standard 4-5 drink criteria (Naimi, Nelson 
& Brewer, 2010). Though this pattern of drinking may be a common trend among college 
students (SAMHSA, 2015), it is actually adults over the age of 26 that are responsible for the 
majority - about 70 percent - of binge episodes (Naimi et al., 2003). In fact, the recent climb in 
numbers is most attributable to older (i.e. ages 65+) adults (Grant et al., 2017).  
In order to combat the health crisis that stems from alcohol misuse, it is first necessary to 
understand the neurobiology involved in excessive alcohol consumption, and how this relates to 
binge drinking and alcohol dependence. The former will be investigated in the current study, 
with hopes of identifying neural systems that may be potentiating binge drinking, and developing 
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potential pharmacological methods to prevent such alcohol misuse from becoming alcohol 
dependence.  
Animal models of alcohol consumption  
Animal models provide an alternative approach to studying the neurobiological 
mechanisms underlying alcohol intake in humans. However, due to obvious differences between 
humans and rodents, the validity of traditional models is questionable, limiting the usefulness of 
such procedures. For instance, many studies use alcohol-preferring strains of mice to control for 
variability in alcohol preference, but even this does not necessarily indicate that intake is any 
more attributable to alcohol’s pharmacological effects than to normal behaviors of the species 
(Spanagel, 2001). Likewise, these alcohol preference models do not provide practical means for 
developing prevention methods. Such limitations have led researchers to divert focus to 
developing several different models, each specific to certain facets of alcohol consumption. This 
transition has enhanced the role of animal models in understanding the neurobiology of alcohol 
consumption, enabling further exploration into potential sources of treatment and prevention. 
The point-of-no-return model, for example, not only proved that an irreversible “loss of control” 
exists in alcohol addiction, but also pharmacologically validated this finding by manipulating the 
system involved (i.e. the dopaminergic system). Though insightful, this method and many others 
entail months to years of experimenting (Spanagel, 2001). As such, a procedure to mimic binge 
drinking is distinctive in the sense that it must involve reaching a minimum BAC – a measure 
dependent upon both ethanol intake and time. Moreover, an appropriate model must characterize 
the voluntary consumption of alcohol, for the purpose of intoxication. Whereas several 
techniques fulfill the BAC criterion, very few models accurately depict the greater scope of 
binge drinking in humans.  
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One approach, the “drinking in the dark” (DID) procedure, stands out for its simple, yet 
particularly valid and consistent representation of human binge drinking. This protocol takes 
advantage of the dark-cycle of an ethanol-preferring strain of mice (e.g. C57BL/6J), giving them 
the opportunity to consume ethanol at a point when their ingestive behaviors are high, despite the 
evidence that ethanol intake is not motivated by caloric need (Rhodes, Best, Belknap, Finn & 
Crabbe, 2005; Thiele & Navarro, 2014). More specifically, beginning 3 hours into the mice’s 
dark cycle, their water bottles are replaced with a solution of 20 percent ethanol for 2-4 hours 
(Rhodes et al., 2005). The model has been especially influential in studying the neuromodulators 
and potential pharmacological treatments of this pattern of drinking. For example, in studying 
the role of the GABAergic system in binge-like ethanol drinking, a number of studies have used 
the DID procedure to demonstrate fluctuations in alcohol consumption following administration 
of GABA agonists to the ventral tegmental area (VTA). Similarly, it has been used to confirm 
the influence of the dopaminergic system in modulating excessive ethanol intake (Sprow & 
Thiele, 2012).   
Involvement of the norepinephrine system in binge drinking 
 While extensive research has supported the notion that the dopamine (DA) system plays a 
role in the incentive motivation associated with the overconsumption of alcohol and other drugs 
(Banerjee, 2014), it is unlikely that this system reinforces the use of alcohol independently. In 
fact, lesions to the DA-mesolimbic system do not significantly alter alcohol-reinforced 
behaviors, indicating that other circuits of neurotransmission may also be influential in the 
reinforcement of intoxication (Rassnick, Stinus & Koob, 1993). Though norepinephrine (NE) is 
a crucial component of the stress system, which partly drives excessive drinking behaviors 
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(Haas-Koffler, Swift & Leggio, 2018), research evaluating this neurotransmitter’s involvement 
in the misuse of alcohol is very limited.  
It is likely that the NE system works in collaboration with DA to mediate the reinforcing 
properties of drugs and alcohol. More specifically, it has been suggested that the locus coeruleus 
(LC), the primary producer of norepinephrine, plays a major role in regulating the ventral 
tegmentum dopaminergic (VTA-DA) neurons that stimulate rewarding effects of alcohol intake 
(West, Boss-Williams, Ritchie & Weiss, 2015). NE nuclei have therefore been implicated in the 
modulation of drug and alcohol-related behaviors more recently. This primarily occurs through 
actions at alpha-1, alpha-2 and beta adrenergic receptors (AR). Whereas alpha-1 and beta 
receptors typically have excitatory effects, alpha-2 receptors are usually located presynaptically 
and bear inhibitory effects (Rang, Ritter, Flower & Henderson, 2014). The NE nuclei send 
signals to various brain nuclei, including the hippocampus, hypothalamus, thalamus, cerebellum, 
cortex and amygdala (Schwarz & Luo, 2015). As such a recognizable structure in the 
neurobiology of alcohol abuse, the amygdala has received considerable attention in this context 
(Kash, 2012). Likewise, the LC-hypothalamic pathway has primarily been evaluated via the 
paraventricular nucleus of the hypothalamus (Alonso, Balmefrezol & Assenmacher, 1986). 
Much less is known about the LC projection to the lateral hypothalamus (LH). This circuit may 
be of particular interest when studying the effects of NE, since this structure plays a vital role in 
homeostatic functions (Sessler, Cheng & Waterhouse, 1988), and therefore modulates a wide 
variety of behaviors including consumption of rewarding stimuli such as alcohol (Leibowitz, 
2007). In fact, ethanol-induced c-Fos expression, indicative of neuronal activity, has highlighted 
the prominence of this pathway in both involuntary (Thiele, Cubero, Van Dijk, Mediavilla & 
Bernstein, 2000) and voluntary (Burnham, 2017b) models of binge drinking.  
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A potential discrepancy arises when considering how ingestive behaviors are affected by 
the manipulation of neuronal activity within the LC and LH, individually. When activating NE 
neurons within the LC, ethanol intake and sucrose intake, is diminished (Burnham, 2017a). In a 
study conducted by Stamatakis et al. (2015), inhibition of LH glutamate increased the 
consumption of a liquid caloric reward. Likewise, suppression of inhibitory LH GABAergic 
neurons reduced appetitive and consummatory behaviors while activation of these neurons had 
the opposite effect (Jennings et al., 2015). There is also evidence that, despite the LH’s primary 
role in regulating homeostasis, neurons in this region do not drive consummatory behaviors for 
the purpose of maintaining homeostatic caloric balance (Navarro et al., 2016). These findings 
indicate that further investigation of the LC-LH pathway is needed to clarify its implications in 
the use of alcohol.  
Current Study 
 Previous studies conducted within this lab have implemented the DID procedure to 
evaluate the influence of the LC-LH pathway on binge drinking, demonstrating that 
manipulation of this pathway significantly alters binge-like ethanol consumption (Burnham, 
2017a). Alpha-1 AR agonism within the LH showed time-and-dose-dependent decreases in 
ethanol, but not sucrose, intake. Contrarily, beta AR agonism showed a sex-dependent effect, 
decreasing ethanol consumption in females exclusively (Burnham, 2017a). Alpha-2 receptors, 
however, have yet to be studied in this paradigm despite evidence that they contribute to the 
action of ethanol (Mao & Abdel-Rahmin, 1996). Unlike alpha-1 and beta ARs, alpha-2 receptors 
have an inhibitory effect on norepinephrine-releasing neurons, thereby reducing the amount of 
NE released into the synapse. Thus, alpha-2 AR antagonists enhance the release of NE by 
hindering the inhibitory influence (Pertovaara, Haapalinna, Sirvio & Virtanen, 2005).  
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 In this study, we first aim to explore the effects that such antagonists have on binge 
drinking. More specifically, we will evaluate the impact of an alpha-2 AR antagonist, 
atipamezole, on the LH alpha-2 AR-driven ethanol consumption, hypothesizing that infusing 
atipamezole into the LH will reduce binge-like ethanol consumption by increasing NE 
availability through blockade of alpha-2 ARs. Once this last subset of ARs has been assessed 
within the LH, we will follow by testing the effects of a systemic (non-site-directed) NE-specific 
reuptake inhibitor, reboxetine, to further evaluate how the NE system, as a whole, may mediate 
alcohol intake. We hypothesize that infusing reboxetine intraperitoneally will decrease binge-like 
ethanol consumption by restricting the reuptake of NE in the synaptic cleft and increasing 
extracellular NE throughout the CNS. 
Method 
Animals 
 In the current study, subjects included C57BL/6J mice (12 male, 13 female) 8 – 10 weeks 
old at the beginning of the experiment. The animals were individually housed in ventilated cages 
in a 12-hour reverse light-dark cycle room kept at room temperature (22 – 25°C). They had free 
access to Purina RMH 3000 and water when testing was not taking place. Four animals (2 males, 
2 females) were not included in data analysis due to clogged cannulas or lack of baseline 
drinking. Protocols were in compliance with the National Institute of Health guidelines, and 
approved by the Institutional Animal Care and Use Committee at the University of North 
Carolina at Chapel Hill. 
Surgery  
All subjects underwent surgery wherein stainless steel cannulas were implanted into the 
target region to enable direct drug administration. Prior to surgery, each mouse was weighed and 
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respectively anesthetized through intraperitoneally-injected ketamine (66.7mg/kg) and xylazine 
(6.67 mg/kg). Cannulas were implanted bilaterally into the LH (AP -1.1, ML +/- 1.1, DV -5.1 
coordinates; Figure 1) based on coordinates from the atlas The Mouse Brain in Stereotaxic 
Coordinates (Franklin & Paxinos, 2008) and an interograde tracing experiment demonstrating 
noradrenergic nuclei innervation of this area (Burnham, 2017a). Dummy cannulas were inserted 
to prevent contamination. Immediately after surgery, topical analgesic cream (containing 25mg/g 
of Lidocaine and 25 mg/g of Prilocaine) was applied to the area surrounding the cannula. Mice 
were given a 2-week recovery period to adjust and ease distress before testing began.  
Drinking in the Dark (DID) Procedure 
 Voluntary binge-like ethanol consumption was induced using a standard 4-day DID 
paradigm. Approximately three hours into the dark cycle, home cage water bottles were removed 
and replaced with pipettes containing 20% ethanol, which the mice were able to access for 2 
hours on days 1 – 3 (training days) and on day 4 (test day). At the end of this 2-hour period, 
pipette volume was measured to assess ethanol intake (i.e. the difference in pipette volume 
between the start and end of the 2-hour free-access period), and home cage water bottles were 
returned. On test days, blood was taken immediately following the 2-hour period of ethanol 
access in order to assess blood ethanol concentration (BEC) levels. Blood samples were collected 
by the nicking of lateral tail veins, and BEC’s were figured by an alcohol analyzer machine 
(Analox Instruments, Lunenburg, MA). See Thiele and Navarro (2014) for additional details on 
this procedure.  
Experimental Design 
 Subjects were either tested on Wednesdays, Thursdays or Fridays, depending on which 
weekday corresponded with day 4 of their DID cycle. Weight was consistently measured on 
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Wednesdays for all subjects. Before each testing period, an individual unaffiliated with this study 
randomly assigned subjects to weekly conditions. This accounted for potential order effects and 
ensured that experimenters were kept blind to treatment conditions for all testing procedures. 
 Experiment 1.  
Ethanol testing. This experiment involved three conditions: high drug dose (15.0 μg 
atipamezole/brain hemisphere), low drug dose (1.5 μg atipamezole/brain hemisphere) and 
vehicle (saline solution containing no atipamezole). On each of the test days over a 3-week 
period, every mouse received the vehicle, as well as both doses of the drug, enabling the subjects 
to serve as their own controls. Substances were labeled as 1, 2, and 3, and animals were 
randomly assigned to a different substance for each week.  
On its respective test day, each mouse was removed from its cage and held while 3.0 μL 
of either substance 1, 2 or 3 (whichever it was assigned to for that week) was microinfused 
directly into the LH. After receiving its infusion, the animal was returned to its cage, and 
approximately 20 minutes later, its water bottle was replaced with a pipette full of ethanol. 
Pipette volumes were measured every 30 minutes until home cage water bottles were returned 
and blood samples were collected (after 2 hours).  
Sucrose testing. Following ethanol testing, mice were once again exposed to two 
conditions – the low drug dose (1.5 μg atipamezole/brain hemisphere) and vehicle – for sucrose 
testing. This procedure took place over a 2-week period, such that subjects were randomly 
assigned to receive substance 1 or 2 the first week, and the other substance the second week.  
On injection day, each mouse was removed from its cage and held while 3.0 μL of either 
substance 1 or 2 was microinfused directly into the LH. After receiving its infusion, the animal 
was returned to its cage, and approximately 20 minutes later, its water bottle was replaced with a 
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pipette full of sucrose water. Pipette volumes were measured every 30 minutes over a 2-hour 
period. Home cage water bottles were then returned.  
Locomotor Testing. All animals participated in locomotor testing to compare the overall 
locomotor and anxiety-like-related effects between the drug condition and a control condition. In 
this procedure, each mouse was removed from its home cage and held while 3.0 μL of either the 
drug (1.5 μg atipamezole/brain hemisphere) or control (vehicle) solution was infused directly 
into the LH. These conditions were randomly assigned prior to testing. Animals were then placed 
in a Versamax animal activity chamber, where locomotor activity was monitored and recorded 
for 2 hours. All mice were then returned to their home cages.  
Data Analyses. Because the purpose of this study was to explore the effects of an alpha-2 
AR antagonist on binge drinking, BEC’s were evaluated to ensure that there were no outliers. 
Moreover, accurate identification of, and cannula-placement into, the LH was verified for 20 
subjects (Figure 2). One animal received injections in sites that did not align with the LH 
coordinates previously established (Burnham 2017a; Franklin & Paxinos, 2008) and was 
therefore excluded from data collection.   
This repeated measures experiment was carried out using a Latin square design. Analyses 
of variance (ANOVA) tests were used to analyze the effects of the three different treatment 
conditions on binge-like ethanol consumption as well as sucrose consumption. Sex differences in 
ethanol intake were then assessed using a 2 (sex: male, female) x 3 (infusion substance: high 
drug dose, low drug dose, vehicle) repeated measures two-way ANOVA. Follow up t-tests were 
conducted when necessary. Post-hoc tests were conducted when appropriate. All analyses were 
performed in SPSS (Version 18.0).  
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Locomotor activity was analyzed by the VersaMax Analyzer. The horizontal X-Y activity 
was evaluated by an unpaired t-test to determine whether drug administration altered the time 
spent in the center of the chamber, in which case any effect on ethanol consumption could be 
secondary to anxiogenic effects. The total distance travelled was also assessed by an unpaired t-
test to account for the possibility of altered locomotor activity to confound any effect on ethanol 
consumption.   
Experiment 2. Subjects were given 2 weeks of downtime in between Experiment 1 and 
Experiment 2.  
Ethanol Testing. This experiment involved two conditions: experimental drug (10 mg/kg 
reboxetine) and vehicle (a saline solution containing no drug). Drug dose was based on previous 
experimentation with reboxetine in C57BL/6J mice (Roni & Rahman, 2015). Over a 2-week 
period, every mouse received the vehicle and the drug in a random order, enabling the subjects to 
act as their own controls.  
On test days, each mouse was removed from its cage to receive a predetermined amount 
of material 1 or 2 (based on weight) via a single intrapertoneal (i.p.) injection. Animals were then 
returned to their cages, and approximately 10 minutes later, water bottles were replaced with 
pipettes full of ethanol. Pipette volumes were measured every 30 minutes until home cage water 
bottles were returned and blood samples were collected (after 2 hours).  
Sucrose Testing. Following ethanol testing, subjects were randomly assigned to either 
the drug condition or the vehicle control condition for sucrose testing. On its respective test day, 
each mouse was removed from its cage and injected intraperitoneally with its predetermined 
amount of material 1 or 2. Animals were then returned to their cages, and approximately 10 
minutes later, water bottles were replaced with pipettes full of sucrose water. Pipette volumes 
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were measured every 30 minutes for a 2-hour period. Home cage water bottles were then 
returned.  
Locomotor Testing. All animals participated in locomotor testing to assess the overall 
locomotor and anxiety-related effects of reboxetine and determine whether further dose-
dependent ethanol testing was necessary. In this procedure, each mouse was removed from its 
home cage and given an i.p. injection of either a low (5 mg/kg) or high (10 mg/kg) dose of 
reboxetine or vehicle. These conditions were randomly assigned prior to testing. Animals were 
then placed in a Versamax animal activity chamber, where locomotor activity was monitored and 
recorded for 2 hours. All mice were then returned to their home cages.  
Data Analyses. The analysis of BEC’s revealed no significant outliers, enabling all 21 
animals to be included in data collection for Experiment 2.   
This repeated measures experiment was carried out using a Latin square design. Both t-
tests and ANOVA tests were used to analyze the effects of the drug condition on binge-like 
ethanol and sucrose consumption. A paired-samples t-test was used to assess how ethanol 
consumption differed when the animals were exposed to the drug vs. when they were 
administered the vehicle solution. Furthermore, sex differences in ethanol intake were assessed 
using a 2 (sex: male, female) x 2 (infusion substance: drug, vehicle) repeated measures two-way 
ANOVA. Because animals were only exposed to one of the two conditions for sucrose testing, 
an independent samples t-test was used to compare the effects of drug condition vs. vehicle on 
sucrose consumption. Post-hoc tests were conducted when appropriate. All analyses were 
performed in SPSS (Version 18.0).  
Locomotor activity was analyzed via the VersaMax Analyzer. The horizontal X-Y 
activity and total distance travelled in the first 5 minutes within the chamber, in particular, were 
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evaluated by a one-way ANOVA to determine if either dose of reboxetine prompted locomotor 
and/or anxiogenic activity that significantly differed from that elicited by vehicle infusions.  
Post-Experiment Immunohistochemistry 
 All subjects were perfused with phosphate buffered saline (PBS) and 4% 
paraformaldehyde via a Masterflex L/S perfusion pump (catalogue #7200-12, Cole-Parmer, 
Vernon Hills, IL). Brains were then extracted and stored individually in 4% paraformaldehyde at 
4° C until slicing, when brains were sectioned into 40 μm slices via vibratome (model VT1000 
S, Leica Biosystems, Buffalo Grove, IL). All tissue was stored in cryopreserve within a freezer at 
-20° C for approximately 21 days. Finally, tissue was mounted onto glass slides and then 
counterstained and cover-slipped with Permount mounting solution for subsequent microscopic 
analyses.   
Results 
Experiment 1 
 A one-way repeated ANOVA revealed no significant effect of drug dose on total ethanol 
consumption [F (2, 028 = 0.129, p = 0.879]. A two-way repeated ANOVA showed a non-
significant main effect of sex [F (1, 14) = 2.155, p = 0.125] and a significant sex by drug dose 
interaction [F (2, 28) = 3.925, p = 0.031] (Figure 3A) with the lower dose reducing ethanol 
consumption in females only. Interestingly, a unpaired t-test indicated a higher ‘baseline’ ethanol 
intake in females, shown by a significantly different [t(18) = 2.42, p = 0.026] vehicle-induced 
ethanol consumption in males vs. females. In females, the lower drug dose appeared to reduce 
ethanol consumption to male consumption-equivalent levels. A similar, but non-significant, trend 
was represented by BEC analyses.  
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 Additionally, there was no main effect of drug dose on sucrose consumption. There was, 
however, a significant sex x infusion condition interaction [F (1, 18) = 7.451, p = 0.014] with the 
lower drug dose reducing consumption in females (Figure 3B). The follow-up bonferroni post-
hoc test indicated that there was a significant difference in sucrose intake when females were 
given the vehicle vs. when they were given the lower drug dose (p = 0.034). No main effect of 
sex on sucrose intake was detected.  
 An unpaired t-test [t(8) = 1.274, p = 0.238] failed to reveal a significant difference in  
locomotor activity between the females that received vehicle and those that received the low 
drug dose (Figure 4A), indicating that the reduction in consumption was not secondary to a drug-
mediated alteration in locomotor state. Anxiety-related activity was also assessed by an unpaired 
t-test, which showed no significant difference [t(8) = 0.459, p = 0.658] in exploratory behavior in 
the first 5 minutes within the chamber (Figure 3B).   
Experiment 2 
 A paired-samples t-test indicated a significant effect of drug on total ethanol intake [t(20) 
= 2.636, p = 0.016] and BEC levels such that reboxetine administration elicited lower levels of 
ethanol consumption (Figure 5A). To determine if this effect was specific for sex, a repeated-
measures two-way ANOVA was conducted and the ethanol consumption by sex interaction was 
non-significant [F (1, 30) = 0.017, p = 0.897]. There was also no significant main effect of sex.  
 According to an unpaired t-test, there was a significant effect of drug dose on sucrose 
consumption [t(19) = 3.487, p = 0.003] (Figure 4B). A two-way ANOVA (sex by drug) 
administration failed to reveal main effects of sex [F (1, 17) = 1.487, p = 0.239] or an sex x drug 
interaction [F(1,17) = 0.245, p = 0.626] on consumption.  
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A one-way ANOVA was conducted to evaluate the total distance traveled, which 
accounts for the possibility of drug-induced altered locomotor activity. There was no main effect 
of injection substance on locomotor activity within the first 5 minutes [F (2,18) = 1.682, p= 
0.214], nor did locomotor activity significantly differ among groups for any 5-minute bin 
throughout the 120-minute test period [F (2,18) = 3.005, p = 0.075] (Figure 6A). There was also 
no significant difference between groups in center-time behavior in the first 5 minutes within the 
chamber [F(2, 28) = .0427, p = 0.659] (Figure 6B). Lastly, there was no main effect of sex or 
interaction between sex and infusion condition on either locomotor activity or anxiogenic 
behavior.  
Discussion 
While it is evident that the noradrenergic system plays a significant role in mediating 
alcohol use, much is still unknown about the relative influence of specific noradrenergic 
pathways and how this relates to the development of alcohol use disorder. Efforts to implicate 
AR subtypes in the treatment of excessive alcohol use typically focus on individuals who are 
already alcohol-dependent, overlooking the opportunities for prevention. The current study 
addresses the matter with a more novel approach, aiming to reduce alcohol intake before 
dependence has transpired.  
In our first experiment, LH alpha-2 AR antagonism via atipamezole elicited a sex-
dependent effect, significantly reducing ethanol consumption in females but not males. These 
results were somewhat similar to those of the preliminary studies conducted within this lab, 
which evaluated the effects of heightened LH NE via alpha-1 and beta AR agonism. Whereas the 
alpha-1 agonist resulted in time-and-dose-dependent decreases in ethanol consumption, the effect 
of the beta agonist paralleled alpha-2 antagonism, reducing ethanol intake among female subjects 
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only (Burnham, 2017a). This sex-dependent effect may be partly explained by an interaction 
between the NE system and female estrogen levels. Zhang et al. (2017) concluded that estradiol 
(E2) may participate in the regulation of NE synthesis, degradation and reuptake after noticing 
diminished LC NE levels in ovariectomized rats. Though the mechanisms underlying its 
modulatory effects are uncertain, E2 administration greatly enhanced NE levels within the LC. 
Another study showed that E2’s influence on the noradrenergic system can be explained, at least 
in part, by the decreased expression and altered functions of alpha-2 receptors (Hajagos-Tóth et 
al., 2016). This could explain why female C57BL/6J mice generally consume more alcohol than 
male counterparts (Rhodes et al., 2005), which was observed during ‘baseline’ vehicle-induced 
levels of ethanol consumption in the present study as well. This effect is currently being 
investigated in a clinical trial comparing the effectiveness of guanfacine, an alpha-2 agonist, in 
treating alcohol-dependent women versus men (NCT03137082). Further exploration of this 
interaction is needed, but it is possible that a similar sex-specific process takes place among ARs 
in the LH, yielding higher NE levels and amplified instances of atipamezole-induced 
consumption reduction in females producing E2. This suggests that sex-specific pharmacological 
treatments may be a useful in order to reduce overall alcohol use.  
Regardless of the factors contributing to the sex-specific effect, the fact that atipamezole 
resulted in any reduction of ethanol consumption seems counterintuitive when considering the 
abundance of past studies that have demonstrated lessened alcohol intake in response to NE-
reducing agents. This inconsistency is stressed in a recent review by Haass-Koffler, Swift and 
Leggio (2018), which provides ample evidence of studies that have successfully decreased 
alcohol with alpha-1 and beta blockers and alpha-2 agonists. Although it would provide a 
reasonable explanation of this discrepancy, it is improbable that anxiogenic- or hypokinetic-
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induced effects of atipamezole confounded the altered consumption within our study, as there 
was no significant difference in locomotor activity following drug administration.   A more 
convincing argument arises when considering the population at hand. In contrast to the present 
study, alcohol-dependent populations have been the primary targets when evaluating the 
consequences of NE reductions. For example, the clinical significance of clonidine, an alpha-2 
AR agonist, was stressed when one study reported that it decreased alcohol and sucrose 
consumption in a group of alcohol-preferring (P strain) rats (Rasmussen, Alexander, Malone, 
Federoff & Froehlich, 2009). Though insightful, these results were observed in rats that received 
2-hour access to alcohol 5 days/week, limiting conclusions to populations with such an extensive 
history of alcohol exposure. Based on current evidence of alcohol-induced neuroadaptations 
(Ward, Lallemand & de Witte, 2009), it is likely that the manipulation of alpha-2 receptors 
differentially impacts those engaging in occasional episodes of binge drinking and individuals 
who chronically abuse alcohol. The results of our study are supported by instances of increased 
alpha-2 ARs following 10 days of alcohol vapor exposure (Getachew, Hauser, Csoka, Taylor & 
Tizabi, 2017). This is in contrast to the apparent down regulation of alpha-2 ARs, which is 
assumed to explain the long-term diminished clonidine-induced sedation (Berggren et al., 2003; 
Berggren, Eriksson, Fahlke, Sundkler & Balldin, 2002) and hyper-arousing symptoms witnessed 
among persons experiencing alcohol withdrawal. Given the subnormal function of alpha-2 ARs 
and disinhibition of NE-releasing neurons in chronic abusers, it is probable that alpha-2 agonists 
such as clonidine yield neurochemical effects similar to those achieved by alcohol use, which 
decreases brain NE levels (Fitzgerald, 2013) and apparently self-medicates. The opposite effect 
would need to occur for non-dependent individuals, whose alpha-2 ARs may be up regulated in 
response to alcohol exposure (Getachew et al., 2017). Although most of the literature discussed 
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has manipulated the NE system systemically by peripheral means, evidence of subsensitive 
alpha-2 AR functioning in the hypothalamic-pituitary axis of alcohol-dependent individuals 
(Berggren, Fahlke, Norrby, Zachrisson & Balldin, 2000) suggests that these changes occur in 
various alpha-2 systems within the CNS. Therefore, it is not unlikely that alpha-2 AR 
desensitization takes place within the LH as a part of the transition to alcoholism, potentiating 
elevated NE levels among abusers (Fitzgerald, 2013) and causing outcomes contrary to the ones 
observed among non-alcohol-dependent subjects in the current study. There is also the 
possibility that subsensitive alpha-2 ARs are genetic and serve more as a precursor to alcohol 
abuse, in which case individuals possessing this trait may be more susceptible to alcohol 
dependence. Either theory would explain why our results seem out of line with so many previous 
studies such that inhibition (by an alpha-2 antagonist), rather than stimulation (by an alpha-2 
agonist), of LH alpha-2 ARs resulted in a decreased ethanol intake among females. Future 
research should evaluate how the effects of alpha-2 AR antagonists vary between alcohol-naïve 
and alcohol-dependent populations, as well as those in between.    
Our results indicated that LH alpha-2 inhibition altered the response to sucrose and 
alcohol in a similar manner – i.e. it significantly suppressed sucrose consumption in females 
only. Rasmussen et al. (2014) also observed corresponding effects among sucrose and alcohol 
intake when investigating the alpha-2 ARs from a more global perspective via i.p. injections. 
Though decreased alcohol intake in P rats was observed by alpha-1 AR antagonists, such as 
doxazosin (O’Neil, Beckwith, Kincaid & Rasmussen, 2013) and prazosin (Rasmussen, 
Alexander, Raskind & Froehlich, 2014), their effects were not accompanied by altered sucrose 
intake. No such effect was observed in the preliminary testing of the alpha-1 and beta agonists 
either (Burnham, 2017a). This suggests that the effects of alpha-2 AR manipulation may be less 
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specific to alcohol than those of alpha-1 AR manipulation. Based on the fact that LC activation 
decreases alcohol and sucrose intake (Burnham, 2017a) and LC GABA activation (Jennings et 
al., 2015; Navarro et al., 2016) increases general feeding behaviors, it would then be plausible to 
argue that the LC and LH are differentially influenced by alpha-1 and alpha-2 ARs. This notion 
is supported by evidence of uneven distributions of AR subtypes (Leibowitz, 1970), but must be 
interpreted carefully, as the effects of manipulating activity within a single brain region may or 
may not generalize to those of peripheral administration of similar compounds, and vice-versa.   
In conjunction with previous studies, our findings indicate that the LC-LH noradrenergic 
pathway may be a significant constituent of the neuroplasticity in alcoholism. This stresses the 
importance of discovering pharmacological therapies that combat the excessive use of alcohol 
specifically before dependence has developed, as they are likely to have different levels of 
effectiveness once brain adaptations have occurred. Additionally, the sex-specific effect of 
atipamezole on alcohol consumption and sucrose intake suggest that LH alpha-2 receptors 
interact with female and male sex hormones differently and bear influence that is non-selective 
for alcohol. Although it is evident that the LC-LH pathway has some influence on the use of 
alcohol, its role may be more moderate than other efferent projections of the LC.  
In conclusion, this experiment is not short of limitations. First and foremost, while 
atipamezole’s high selectivity (Bialer et al., 2004) for alpha-2 ARs makes it unlikely that our 
results are an effect of manipulations to other receptor types, it is possible that our findings are 
not limited to alpha-2 ARs within the LH region. Although cannula placement outside of the 
established coordinates for the LH qualified as exclusion criteria, we cannot not rule out the 
possibility that atipamezole travelled beyond the injection site and posed effects on alpha-2 ARs 
in other brain regions. Furthermore, while the aim of this experiment was to clarify the role of 
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the LC – LH pathway in alcohol use, the high interconnectivity of the brain makes it difficult to 
pin any effects solely to one receptor type within one brain pathway without completely isolating 
the pathway. Because we only manipulated alpha-2 ARs within the LH, we cannot attribute the 
outcomes of this study to the LC – LH pathway anymore than we can attribute them to other 
noradrenergic nuclei that project to the LH, such as the A2. As such, more specificity would be 
needed in order to draw conclusions regarding alpha-2 ARs within the LC – LH pathway. 
Additionally, limited experimentation with atipamezole left us with an imprecise understanding 
of its pharmacokinetics in C57BL/6J mice and how our site-directed approach of administration 
may have affected the rate of absorption and elimination. In attempt to narrow this uncertainty, 
consumption measurements were taken every 30 minutes beginning about 20 minutes after drug 
administration based on reports of rapid absorption in rats (Bialer et al., 2004). No significant 
differences were found, suggesting that the drug was active throughout the 2-hour alcohol free-
access period.  
The results obtained in Experiment 2 confirm the significance of reboxetine, a selective 
NE reuptake inhibitor, in reducing binge-like alcohol intake. Thus, it would appear that 
reboxetine is an effective therapeutic agent for excessive alcohol use. These results are 
unsurprising when considering the effectiveness of reboxetine in treating disorders that often 
accompany alcohol use, such as anxiety (Versiani et al., 2002) and depression (Burrows, 
Maquire & Norman, 1998). Moreover, taken together, these findings suggest that reboxetine’s 
potential could be maximized in targeting alcohol use, as it bears synergistic effects that could 
reduce the hindrance that comorbid anxiety and depression tend to have on alcohol treatment 
(Burns, Teesson & O’Neill, 2005). In fact, substantial literature reports corresponding 
improvements in social functioning and mental health following reboxetine exposure. It is also 
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noteworthy that the administration of reboxetine resulted in a significant decrease in sucrose 
consumption, indicating that it is non-selective for alcohol and may, more generally, reduce the 
value of rewarding stimuli. Likewise, an alternative argument could be that the observations in 
this study were merely a result of antidipsogenic effects, which would imply that reboxetine 
reduces consummatory and appetitive behaviors, regardless of the stimuli. These concepts are 
supported by studies that showed reboxetine may successfully treat binge eating disorder 
(Silveira, Zanatto, Appolinário & Kapczinski, 2005) and bulimia nervosa (Fassino, Daga, 
Boggio, Garzaro & Pierò, 2004). It is unlikely that the alterations in consumption reflected a 
secondary effect of impaired motor function, or anxiety-like behaviors, as reboxetine did not 
significantly alter locomotor activity during the 2-hour test. Experiment 2 further uncovers the 
historically overlooked influence that the noradrenaline system has on alcohol use, and 
legitimizes the systemic use of reboxetine in preventing alcohol use disorder.    
This experiment has its own set of limitations that must be addressed. First of all, it is 
noteworthy that, due to animal costs and time, these manipulations were performed on the same 
animals used in Experiment 1. Thus, by the time of this experiment, animals were relatively old 
and possibly fatigued by the procedure of Experiment 1. Though we did not find evidence to 
support it, we cannot rule out the possibility that LH-alpha-2 antagonism and/or the stressful 
conditions inherent in surgery did not alter signaling within the animals. This could potentially 
disrupt NE signaling systems and modify the effects of reboxetine in Experiment 2. Moreover, 
given normative age-related changes of the noradrenergic system (Daly, Goldberg & Roberts, 
1989), we may have observed different effects had Experiment 2 been carried out before 
Experiment 1, when animals were 8 – 10 weeks old. Secondly, though a significant reduction of 
alcohol consumption was achieved, our procedure left us unable to draw conclusions regarding 
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the generalizability of reboxetine, as we only measured the response to sucrose and alcohol – 
both of which are presumably rewarding stimuli whose intake is motivated by positive 
reinforcement within non-dependent subjects. We also failed to depict how the effects of 
reboxetine may vary according to dose despite evidence that reboxetine dose-dependently 
increases extracellular NE levels in the brain (Page & Lucki, 2002). We did, however, show that 
there was no significant difference in locomotor and anxiety-related activity between a lower 
dose of reboxetine and the dose used throughout ethanol and sucrose testing. Furthermore, the 
drug was administered peripherally, limiting the scope of our conclusions. While it is generally 
regarded as a selective NE-reuptake inhibitor, it has been shown to alter extracellular dopamine 
levels in the CNS (Page & Lucki, 2002). The lack of specificity, alongside the drug’s efficacy in 
a variety of other disorders, leaves us questioning how reboxetine may interact with the reward 
system to produce different outcomes according to where one lies on the naïve to dependent 
spectrum of alcohol use. Further investigation of its impact within specific pathways and brain 
regions is crucial for a more precise understanding of the role it could play in the treatment of 
alcohol abuse.  
This study emphasizes the long-time neglected pharmacological potential of the 
noradrenaline system in preventing alcohol addiction. Though the role of NE in the development 
of alcohol dependence has received increasing attention in recent years, precise mechanistic 
interpretations of its influence remain unclear. Further investigation into specific brain pathways 
that mediate excessive alcohol consumption will fill this gap, facilitating the development of new 
therapies and improving the clinical importance of currently available ones. 
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Figure Captions 
Figure 1. Lateral hypothalamus (LH) region, taken from The Mouse Brain in Stereotaxic 
Coordinates, with approximate cannula tip locations designated by black points (Franklin & 
Paxinos, 2008).  
Figure 2. Indentation modeling accurate cannula placement within the lateral hypothalamus 
(LH).  
Figure 3. Atipamezole-elicited ethanol consumption (A) and sucrose consumption (B) by sex. 
Figure 4. Atipamezole-induced locomotor activity (A) and anxiety-related behavior (B). 
Figure 5. Reboxetine-elicited ethanol consumption (A), BEC levels (B) and sucrose intake (C). 
Figure 6. Reboxetine-induced locomotor activity (A) and anxiety-related behavior (B). 
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